CN116162555A - Engineering bacterium for producing citric acid and construction method and application thereof - Google Patents
Engineering bacterium for producing citric acid and construction method and application thereof Download PDFInfo
- Publication number
- CN116162555A CN116162555A CN202111407487.1A CN202111407487A CN116162555A CN 116162555 A CN116162555 A CN 116162555A CN 202111407487 A CN202111407487 A CN 202111407487A CN 116162555 A CN116162555 A CN 116162555A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- citric acid
- endogenous
- seq
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 title claims abstract description 237
- 241000894006 Bacteria Species 0.000 title claims abstract description 36
- 238000010276 construction Methods 0.000 title abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 24
- 230000002829 reductive effect Effects 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 229920001184 polypeptide Polymers 0.000 claims description 90
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 90
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 90
- 108090000623 proteins and genes Proteins 0.000 claims description 85
- 241000228245 Aspergillus niger Species 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 20
- 241000499912 Trichoderma reesei Species 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 230000002779 inactivation Effects 0.000 claims description 15
- 241000351920 Aspergillus nidulans Species 0.000 claims description 11
- 240000006439 Aspergillus oryzae Species 0.000 claims description 11
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 11
- 108091026890 Coding region Proteins 0.000 claims description 10
- 238000013518 transcription Methods 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 10
- 108010075600 citrate-binding transport protein Proteins 0.000 claims description 9
- 230000008034 disappearance Effects 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 241000228150 Penicillium chrysogenum Species 0.000 claims description 8
- 241001313536 Thermothelomyces thermophila Species 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 7
- 238000013519 translation Methods 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 241001370055 Aspergillus niger CBS 513.88 Species 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 241000228212 Aspergillus Species 0.000 claims 5
- 239000000843 powder Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 51
- 238000000855 fermentation Methods 0.000 description 11
- 230000004151 fermentation Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 108091027544 Subgenomic mRNA Proteins 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 102000001253 Protein Kinase Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 108060006633 protein kinase Proteins 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 238000012795 verification Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000001938 protoplast Anatomy 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 3
- 244000301083 Ustilago maydis Species 0.000 description 3
- 235000015919 Ustilago maydis Nutrition 0.000 description 3
- 231100000221 frame shift mutation induction Toxicity 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 2
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 108020005075 5S Ribosomal RNA Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011090 industrial biotechnology method and process Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 101150054232 pyrG gene Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
- C12P7/48—Tricarboxylic acids, e.g. citric acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11011—Protein-serine/threonine kinases (2.7.11) cAMP-dependent protein kinase (2.7.11.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses engineering bacteria for producing citric acid, a construction method thereof and a method for producing citric acid by using the strain. The citric acid yield of the engineering bacteria constructed by the invention is improved, so that the production cost can be reduced. Further, the activity of the citric acid transporter is enhanced in engineering bacteria, and the yield of citric acid can be further improved.
Description
Technical Field
The invention relates to the technical field of bioengineering and genetic engineering, in particular to a construction method and application of engineering bacteria for producing citric acid and a method for producing citric acid.
Background
Citric acid is an important organic acid, is a natural preservative and food additive, and is widely applied to industries, foods and cosmetics. Mainly produced by microbial fermentation, and the main production strains thereof comprise yeast and aspergillus niger. Aspergillus niger is the most competitive industrial strain in the citric acid industry, producing citric acid in global annual yields of 200 ten thousand tons with yields exceeding $20 hundred million, and increasing at a rate of 5% per year.
Because of the great difficulty of genetic transformation of aspergillus niger, early researches have mainly focused on optimization of fermentation processes to improve the yield of aspergillus niger, such as continuous optimization of fermentation conditions of carbon source, nitrogen source, pH and the like. In recent years, with the development of metabolic engineering and the continuous development of genetic manipulation tools for aspergillus niger, reports of improving the yield of citric acid through genetic engineering also appear successively, and targets for engineering include increasing the supply of acetyl-coa as a substrate thereof, increasing the excretion of citric acid, increasing respiratory chain regulation and the like. These genetic alterations increase the yield of A.niger citric acid to varying degrees.
However, along with the increasing demand of the global market for citric acid, how to find new transformation targets, and how to construct efficient aspergillus niger engineering bacteria to improve the yield of citric acid and further reduce the production cost are problems to be solved in the field.
Disclosure of Invention
The invention aims to provide engineering bacteria for producing citric acid, a construction method of the bacteria and a method for producing citric acid by using the bacteria.
In a first aspect, the invention provides An engineered bacterium for citric acid production, said strain being modified such that An endogenous active polypeptide is inactivated, wherein said endogenous active polypeptide is An a 01g02600, an01g10200, an02g01210, an02g05870, an02g08630, an02g14400, an05g00280, an07g04000, an08g03270, an08g05190, an09g06580, an13g 00140 or An15g00910, or a homologous gene thereof, corresponding to the aspergillus niger CBS513.88 genome; preferably, the endogenous active polypeptide comprises any of (a) - (b):
(a) Comprising SEQ ID NO:1 to SEQ ID NO:5, and a polypeptide having the amino acid sequence shown in any one of the above.
(b) And SEQ ID NO:1 to SEQ ID NO:5 above 98% and is derived from an endogenous active polypeptide of aspergillus niger.
Preferably, inactivation of the endogenous polypeptide refers to a decrease or disappearance of the activity of the polypeptide or a decrease or disappearance of the expression level of the gene encoding the polypeptide. Still further, inactivation of the endogenous polypeptide may be accomplished by one or a combination of the following methods: partial or complete knockout of the gene encoding the polypeptide; mutation of the coding gene; altering the promoter, translational regulatory region or coding region codon of the coding gene to attenuate transcription or translation; altering the coding gene sequence to make its mRNA stability weakened or make the structure of coded protein unstable; or any other means of inactivating the coding region of the gene by modifying the region adjacent to the region upstream and downstream thereof.
In preferred embodiments, the gene coding sequence is subjected to frameshift mutations, missense mutations, deletions, start codon changes, and the like.
Further preferably, a reduced activity of an endogenous active polypeptide in said strain relative to an unmodified endogenous active polypeptide means that transcription, expression of a gene encoding said endogenous active polypeptide is reduced by at least 30%, preferably by at least 40%, more preferably by at least 50%, such as by at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or is completely absent; or the activity of the endogenous active polypeptide is reduced by at least 30%, preferably by at least 40%, more preferably by at least 50%, e.g. by at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or is completely absent.
Preferably, the engineered bacteria producing citric acid have an increase in citric acid yield of at least 10%, preferably an increase of at least 20%, more preferably an increase of at least 30% compared to a wild type strain comprising the endogenous polypeptide.
Furthermore, the activity of the citrate transporter CexA in the engineering bacteria for producing the citric acid is enhanced.
Preferably, the citrate transporter is a polypeptide with an amino acid sequence shown as SEQ ID NO. 6.
Alternatively, the engineering bacteria for producing citric acid include, but are not limited to, any one of Aspergillus niger (Aspergillus niger), aspergillus nidulans (Aspergillus nidulans), aspergillus oryzae (Aspergillus oryzae), penicillium chrysogenum (Penicillium chrysogenum), trichoderma reesei (Trichoderma reesei), semen Maydis (Ustilago maydis), myceliophthora thermophila (Myceliophthora thermophila), and the like, preferably Aspergillus niger, aspergillus nidulans, aspergillus oryzae, trichoderma reesei, and most preferably Aspergillus niger.
In a specific embodiment of the invention, the endogenous active polypeptide is a polypeptide having an amino acid sequence as set forth in any one of SEQ ID NOs 1-5.
In a second aspect, the invention provides a method of constructing an engineered bacterium for citric acid production, the method comprising modifying a wild-type strain comprising an endogenous polypeptide to inactivate the endogenous polypeptide of the wild-type strain, wherein the endogenous active polypeptide comprises any one of (a) - (b):
(a) Comprising SEQ ID NO:1 to SEQ ID NO:5, and a polypeptide having the amino acid sequence shown in any one of the above.
(b) And SEQ ID NO:1 to SEQ ID NO:5 above 98% or above 99% and is derived from an endogenous active polypeptide of a. Niger.
Preferably, inactivation of the endogenous polypeptide refers to a decrease or disappearance of the activity of the polypeptide or a decrease or disappearance of the expression level of the gene encoding the polypeptide. Still further, inactivation of the endogenous polypeptide may be accomplished by one or a combination of the following methods: partial or complete knockout of the gene encoding the polypeptide; mutation of the coding gene; altering the promoter, translational regulatory region or coding region codon of the coding gene to attenuate transcription or translation; altering the coding gene sequence to make its mRNA stability weakened or make the structure of coded protein unstable; or any other means of inactivating the coding region of the gene by modifying the region adjacent to the region upstream and downstream thereof.
In preferred embodiments, the gene coding sequence is subjected to frameshift mutations, missense mutations, deletions, start codon changes, and the like.
Further preferably, a reduced activity of an endogenous active polypeptide in said strain relative to an unmodified endogenous active polypeptide means that transcription, expression of a gene encoding said endogenous active polypeptide is reduced by at least 30%, preferably by at least 40%, more preferably by at least 50%, such as by at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or is completely absent; or the activity of the endogenous active polypeptide is reduced by at least 30%, preferably by at least 40%, more preferably by at least 50%, e.g. by at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or is completely absent.
Furthermore, the activity of the citrate transporter CexA in the engineering bacteria for producing the citric acid is enhanced.
Preferably, the citrate transporter is a polypeptide with an amino acid sequence shown as SEQ ID NO. 6.
Preferably, the engineering bacteria for producing citric acid include, but are not limited to, any one of Aspergillus niger (Aspergillus niger), aspergillus nidulans (Aspergillus nidulans), aspergillus oryzae (Aspergillus oryzae), penicillium chrysogenum (Penicillium chrysogenum), trichoderma reesei (Trichoderma reesei), semen Maydis (Ustilago maydis), myceliophthora thermophila (Myceliophthora thermophila), and the like, preferably Aspergillus niger, aspergillus nidulans, aspergillus oryzae, trichoderma reesei, and most preferably Aspergillus niger.
In a third aspect, the present invention provides a method of producing citric acid, the method comprising the steps of:
(1) Culturing the citric acid producing strain of the first aspect, or the citric acid producing strain constructed of the second aspect, to produce citric acid; optionally, further comprising:
(2) Separating the citric acid from step (1).
In a fourth aspect, the present invention provides a citric acid producing strain of the first aspect, the use of a citric acid producing strain constructed of the second aspect in the production of citric acid.
Compared with wild type bacteria, the engineering bacteria constructed by the invention have the advantages that the citric acid yield is obviously improved, so that the production cost can be reduced, and the engineering bacteria have practical significance.
Detailed Description
The inventor of the present invention has conducted extensive and intensive studies and has unexpectedly found that inactivation of 5 endogenous polypeptides can increase the yield of citric acid from Aspergillus niger, and significantly increase the acid production level of the strain, thereby completing the present invention.
Definition of terms
The invention uses "endogenous active polypeptide" or "endogenous polypeptide", concretely speaking, refers to 5 proteins with unknown functions, and the invention respectively presumes that Protein Kinase (PKH), cAMP activated protein kinase (SIP), ubiquitin protease cofactor (BRE), protein kinase (SWE) involved in cell division regulation and subunit (CTI) of histone deacetylase complex have amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO: 5.
As used herein, "citrate transporter" or "CexA" refers to an efflux protein capable of transporting intracellular citrate to the outside of the cell. Specifically, the citric acid efflux protein has the amino acid sequence shown in SEQ ID NO. 6, or the derivative protein or polypeptide which is formed by substituting, deleting or adding one or a plurality of amino acid residues in the amino acid sequence shown in SEQ ID NO. 6 and still has the function of the citric acid efflux protein.
The terms "polypeptide", "active polypeptide" and "protein" of the present invention are used interchangeably herein and are polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interrupted by non-amino acids. The term also includes amino acid polymers that have been modified (e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component).
The term "expression" of the present invention includes any step involving the production of a polypeptide, including, but not limited to: transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
The term "exogenous" as used herein means that a system contains materials that were not originally present. For example, a gene encoding a gene that is not originally present in a strain is introduced into the strain by transformation or the like, and is "exogenous" to the strain.
The term "wild-type/endogenous" as used herein refers to an activity of a polypeptide in a microorganism in an unmodified state, i.e. in a natural state.
In some embodiments, wild-type strains of the invention are strains comprising an endogenous polypeptide, which is a polypeptide having an amino acid sequence as set forth in any one of SEQ ID NOs 1-5, or a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to any one of SEQ ID NOs 1-5.
In a specific embodiment, the wild-type strain is a. Niger comprising an endogenous polypeptide. As used herein, "genetic modification" refers to any genetic manipulation of wild-type strains, including but not limited to various molecular biological means.
"sequence homology" and "percent identity" as used herein refer to the percentage of nucleotides or amino acids that are identical (i.e., identical) between two or more polynucleotides or polypeptides. Sequence identity between two or more polynucleotides or polypeptides may be determined by: the nucleotide or amino acid sequences of the polynucleotides or polypeptides are aligned and the number of positions in the aligned polynucleotides or polypeptides that contain the same nucleotide or amino acid residue is scored and compared to the number of positions in the aligned polynucleotides or polypeptides that contain a different nucleotide or amino acid residue. Polynucleotides may differ at one position, for example, by containing different nucleotides (i.e., substitutions or mutations) or by deleting nucleotides (i.e., nucleotide insertions or nucleotide deletions in one or both polynucleotides). The polypeptides may differ at one position, for example, by containing different amino acids (i.e., substitutions or mutations) or by deleting amino acids (i.e., amino acid insertions or amino acid deletions in one or both polypeptides). Sequence identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residue by the total number of amino acid residues in the polynucleotide or polypeptide. For example, percent identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residue by the total number of nucleotide or amino acid residues in the polynucleotide or polypeptide and multiplying by 100.
The term "inactivation of an endogenous polypeptide" as used herein refers to a modification that results in a decrease, attenuation or even complete disappearance of the intracellular activity of a protein in a microorganism as compared to the activity of the protein in its natural state. Including not only effects lower than the original function due to the decrease in the activity of the protein itself, but also the generation of genes that are not expressed, or expression products that are inactive or have reduced activity in spite of the expression. The term "inactivation of an endogenous polypeptide" in the present invention may be accomplished by modification, and also includes, but is not limited to, modification by the following methods: deletion of part or all of the coding gene, frame shift mutation of the gene, attenuation of the transcription or translation strength, or use of a gene or allele which codes for the corresponding enzyme or protein with lower activity, or inactivation of the corresponding gene or enzyme, and optionally a combination of these methods. The reduction of gene expression can be achieved by suitable culture methods or genetic modification (mutation) of the signal structure of gene expression, for example, the signal structure of gene expression is a repressor gene, an active gene, an operator, a promoter, a attenuator, a ribosome binding site, a start codon and a terminator. The terms "deactivated", "reduced or disappeared", "reduced" according to the invention are interchangeable.
The "engineering bacteria for producing citric acid" according to the present invention has a meaning generally understood by those skilled in the art, and means engineering bacteria which can produce citric acid and can accumulate citric acid when cultured in a medium, or can secrete citric acid into the medium, that is, can obtain extracellular free citric acid. The citric acid producing strain of the present invention may be any of eukaryotic cells including, but not limited to, aspergillus niger (Aspergillus niger), aspergillus nidulans (Aspergillus nidulans), aspergillus oryzae (Aspergillus oryzae), penicillium chrysogenum (Penicillium chrysogenum), trichoderma reesei (Trichoderma reesei), aspergillus niger (Ustilago maydis), myceliophthora thermophila (Myceliophthora thermophila), etc., preferably Aspergillus niger, aspergillus nidulans, aspergillus oryzae, trichoderma reesei, most preferably Aspergillus niger, and citric acid producing mutants or strains prepared from the above strains.
The term "transformation" according to the invention has the meaning generally understood by the person skilled in the art, i.e.the process of introducing exogenous DNA into a host. The transformation method includes any method of introducing nucleic acid into cells, including but not limited to electroporation, calcium phosphate (CaPO) 4 ) Precipitation method, calcium chloride (CaCl) 2 ) Precipitation, microinjection, polyethylene glycol (PEG), DEAE-dextran, cationic liposome, and lithium acetate-DMSO.
In the present invention, the culture of the strain may be performed according to a conventional method in the art, including but not limited to well plate culture, shake flask culture, batch culture, continuous culture, fed-batch culture, etc., and various culture conditions such as temperature, time, pH of the medium, etc., may be appropriately adjusted according to the actual situation.
The terms "comprising," "having," "including," or "containing," as used herein, are intended to be inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
As used herein, "about" means: one value includes the standard deviation of the error of the device or method used to determine the value.
As used herein, the term "or" is defined as only alternatives and "and/or" but, unless expressly indicated otherwise as only alternatives or as mutually exclusive between alternatives, the term "or" in the claims means "and/or".
Compared with wild strains, the genetically modified engineering bacteria of the aspergillus niger citric acid have the advantages that the citric acid yield is obviously improved, the production cost of the citric acid can be further reduced, a new thought is provided for the genetic modification of the aspergillus niger, and the engineering bacteria have better industrial application potential.
The technical scheme of the invention will be further described in detail below with reference to specific embodiments. It is to be understood that the following examples are illustrative only and are not to be construed as limiting the scope of the invention. All techniques implemented based on the above description of the invention are intended to be included within the scope of the invention.
Unless otherwise indicated, the starting materials and reagents used in the following examples were either commercially available or may be prepared by known methods. The experimental procedure, which does not address the specific conditions in the examples below, is generally followed by routine conditions such as Sambrook et al, molecular cloning: conditions described in the laboratory Manual (New York: cold Spring Harbor Laboratory Press, fourth edition) or as recommended by the manufacturer.
Examples
Example 1 construction of expression plasmid for sgRNA of endogenous polypeptide encoding Gene
Genome data of Aspergillus niger M202 strain (purchased from Shanghai institute of technology, inc. resource pool, published accession number M202) was mined using a co-expression network analysis of Aspergillus niger (Schape, P., kwon, M.J., baumann, B., jung, S., lenz, S., nitsche, B., paege, N., schutze, T., cairns, T.C., meyer, V.2019, update genome annotation for the microbial cell factory Aspergillus niger using gene co-expression networks Res,47 (2), 559-569), and the homologous genes of the 13 genes in Aspergillus niger CBS513.88 genome were An01g02600, an01g0, an02g01210, an02g05 08630, an02g1440, an02g14400, an02g 85808, an 35 g 0008 and An 35 g 0008, respectively. In order to verify the functions of these genes, 5 genes are preferred in this example by changing spore morphology and the like, careful gene function prediction is performed, the protein shown in SEQ ID NO. 1 is predicted to be a putative Protein Kinase (PKH), the protein shown in SEQ ID NO. 2 is predicted to be a cAMP activated protein kinase (SIP), the protein shown in SEQ ID NO. 3 is predicted to be a ubiquitin protease cofactor (BRE), the protein shown in SEQ ID NO. 4 is predicted to be a protein kinase (SWE) involved in regulation of cell division, and the protein shown in SEQ ID NO. 5 is predicted to be a subunit (CTI) of a histone deacetylase complex, and specific amino acid sequences are shown in SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5, respectively.
The genome of Aspergillus niger M202 is used as a template, an upstream primer and a downstream primer constructed by an sgRNA expression cassette are designed, 5S rRNA of Aspergillus niger itself is used as a promoter, and a GoldenGate method is adopted to construct an expression plasmid of the sgRNA. The Golden Gate reaction product is transformed into escherichia coli Trans-T1, after corresponding recombinant plasmids are extracted, enzyme digestion and sequencing verification are adopted, and expression plasmids pPKH-sgRNA1, pPKH-sgRNA2, pSIP-sgRNA1, pSIP-sgRNA2, pBRE-sgRNA1, pBRE-sgRNA2, pSWE-sgRNA1, pSWE-sgRNA2, pCTI-sgRNA1 and pCTI-sgRNA2 of each protein sgRNA are obtained. The specific primer sequences are shown in Table 1.
TABLE 1 primers for construction of sgRNA expression plasmids
EXAMPLE 2 construction of endogenous polypeptide-inactivating strains
Cas9 protein expression vector pCas9 (see Zhang L, et al dis-ruption or reduced express ion of the orotidine-5' -decarboxylase gene pyrG increases citric acid product ion: a new discovery during recyclable genome editing in Aspergillus niger. M micro Cell face. 2020Mar24; 19 (1): 76), sgRNA expression cassette fragment and donor DNA fragment were co-transformed into protoplast cells of A.niger M202 to construct each gene inactivated strain. The specific operation is as follows:
(1) Preparation of sgRNA expression cassette fragments
PCR amplification was performed using 5S-Fm (SEQ ID NO: 27:GGTTGGAGATTCCAGACTAG) and sgRNA-Rm (SEQ ID NO:28:A AAAAAGCACCGACTCGGTGCCAC) as primers, respectively, using the sgRNA expression plasmid constructed in example 1 as a template, to obtain the sgRNA expression cassette fragments PKH-sgRNA1/PKH-sgRNA2, SI P-sgRNA1/SIP-sgRNA2, BRE-sgRNA1/BRE-sgRNA2, SWE-sgRNA1/SWE-sgRNA2 and CTI-sgRNA1/CTI-sgRNA2, respectively, for each gene knockout.
The PCR reaction was carried out in the form of 5 XFastpfu buffer 10. Mu.L, 10mM dNTPs 1. Mu.L, 2.5. Mu.L each of the upstream/downstream primers, 0.5. Mu.L of the DNA template, fastPfu (TransGene) 1.5.5. Mu.L, and 32. Mu.L of ultrapure water.
The PCR reaction conditions were: pre-denaturation at 95 ℃ for 5min; denaturation at 95℃for 30sec, annealing at 55℃for 30sec, elongation at 72℃for 45sec,35 cycles; finally, the extension is carried out for 10min at 72 ℃. The PCR products were purified and PEG-mediated protoplast transformation was performed.
(2) Preparation of donor DNA fragments
Preparation of donor DNA fragments was accomplished by one-step PCR, designing the upstream and downstream primers containing 5 homology arms, respectively, and carrying out PCR amplification using plasmids pSilent-1 (see Nakayashiki H, hanada S, quoc NB, kadotani N, tosa Y, mayama S.RNA silencing as a tool for exploring gene function in asco mycete fungi.Fungal Genet biol.2005; 42:275-83) as templates to obtain donor DNA fragments for 5 gene knockouts, which were designated as MH-PKH-sgRNA1/PKH-sgRNA2, MH-SIP-sgRN A1/SIP-sgRNA2, MH-BRE-sgRNA1/BRE-sgRNA2, MH-SWE-sgRNA1/SWE-sgRNA2 and MH-CTI-sgRNA 1/CTI-sgRNA2, respectively. The PCR reaction system and the reaction conditions are the same as above, and the related primer sequences are shown in Table 2.
TABLE 2 primers used for preparation of donor DNA
(3) PEG-mediated protoplast transformation
Preparation of a suspension of protoplasts of Aspergillus niger M202 is described in patent CN112250740A. 100. Mu.L of the protoplast suspension, 2. Mu.g of pCas9, 2. Mu.g of the sgRNA expression cassette fragment and 2. Mu.g of donor DNA were taken, 1mL of solution C (Tris-HCl 10mM, caCl 2.54 g/L, PEG6000 50% (w/v), pH 7.5) was added to it, ice-washed for 10min,2mL of solution B and mixed well. Uniformly mixing with the preheated upper layer culture medium MMSH containing hygromycin, and then spreading on a lower layer culture medium MMSH flat plate. The plates were incubated in a 30℃incubator for 3-5 days until transformants developed.
(4) Genotyping of genetically inactivated strains
Extracting genome DNA of the transformant after secondary passage and purification by adopting a novel plant genome extraction kit DP350 of the plant, and then carrying out gene PCR verification on the transformant by using the extracted genome DNA as a template and using genome up-and-down verification primers of each gene. The specific sequences of the primers are shown in Table 3.
Table 3 verification primers for Gene-inactivated strains
The PCR reaction system and the PCR reaction conditions are the same as above. And (3) carrying out 1% agarose gel electrophoresis (150V voltage, 20 minutes) on the PCR amplified products, observing gene amplified bands under a gel imaging system, and carrying out sequencing verification on each PCR product to finally obtain 5 strains with predicted protein coding gene knockouts, which are named AndPKH, andSIP, andBRE, andSWE and AndCTI respectively.
EXAMPLE 3 citric acid fermentation of polypeptide-inactivating strains
Each of the gene-inactivated strain AndPKH, andSIP, andBRE, andSWE, andCTI and the control strain M202 was inoculated onto PDA medium at 30℃for 5 days, and spores were collected with 0.9% physiological saline and counted using a hemocytometer. At 10 6 The inoculated amount per mL was inoculated into a citric acid fermentation medium (see patent CN 112250740B), and the culture was carried out at 34℃and 250r/min for 96 hours.
The fermentation supernatant was collected by rapid suction filtration, diluted 10-fold, boiled for 10min, filtered with a filter membrane and tested for citric acid content by HPLC. For specific detection conditions, refer to patent CN112250740a. As a result, the inactivation of each gene can obviously promote the production of citric acid, and compared with the original strain, the citric acid fermentation level of the engineering bacteria inactivated by each endogenous polypeptide is increased to 1.1-1.4 times.
EXAMPLE 4 polypeptide inactivation and enhanced citric acid excretion to increase citric acid fermentation levels
The over-expression plasmid pGm-CexA of the citrate efflux protein (see patent CN 112250740A) was transformed into A.niger strain M202 by the method of example 2 to obtain the over-expression strain AnCex of the citrate efflux protein. Then, 5 genes in the citric acid high-yield strain AnCex are knocked out respectively by adopting the method of the embodiment 1-3, and an inactivated strain AnCdPKH, anCdSIP, anCdBRE, anCdSWE and AnCdCTI are obtained. The method in example 3 is adopted to carry out fermentation verification on the strain, and meanwhile, the strain AnCex is used as a control, so that the inactivation of the gene can further promote the production of citric acid on the basis of strengthening the discharge of citric acid, and compared with the original strain, the fermentation level of citric acid is increased to 2.05-2.5 times.
In addition, by adopting the method of the embodiment 1-3, the invention constructs the single knockout engineering bacteria of other 8 endogenous polypeptide coding genes (homologous genes are An01g02600, an02g01210, an02g05870, an02g14400, an07g04000, an08g03270, an08g05190 and An13g 00140 respectively), and compared with the original strain, the citric acid fermentation level of the single knockout engineering bacteria can be improved by more than 5 percent, which indicates that the knockout of the 8 genes has positive influence on the yield of citric acid.
<110> institute of Tianjin Industrial biotechnology, national academy of sciences
<120> engineering bacterium for producing citric acid, construction method and application thereof
<130> China
<160> 48
<170>PatentIn version 3.5
<210> 1
<211>841
<212> PRT
<213>Aspergillus niger
<400> 1
MDGDLSLSQSLGGLRIANPDDSSLHSSEDAATTPAASAADVTEAELVREPTIISERPASSLSITPPRPSASPSTTDLQDTLTSASVEPAVKPRDNRSSLYNPYSDLPQQTSPQYTPYASSSQSHPAPQSSRPMSAFYANGSTSTLAAAREGSYRIRTDSAASSASESQARAESRGGSAAFQAGVPVRDSNHNDRSYRTAQLPPTNGPMIMRQTSRAHARGGAAPQMGGSPYAMENGPGASSEDWQDRGAAVAVRQEIDANGKPVARYIKKGVRDFSFAHTLGEGSYSTVVLGTDRQTLKEYAIKILDKRHIIKEKKVKYVNIEKDTLNRLTEHPGIVRLYYTFQDERSLYFVLDLCKGGELLGVLKRMTTFDEECTRFYGAQILDTIDYMHKRGVIHRDLKPENVLLDSQMHIKITDFGTAKILKSQRKPQNSSGMPPLDATDIPEEERASSFVGTAEYVSPELLTDKNACKASDLWAFGCIIFQLLAGRPPFKAGNEYQTFQKIVALDYDFPAGFPAVARDLVERLLVLDPARRLPIEHIKNHEFFQGIAWGPDLWKRKAPRLKAYVPPPREPIKLNGGGGEGYASSANPAASSTNVSSRVVPRLVTELPPPSQLDIEWSPVLTKTNERILKLGNLVVLSSPAAHSPVSKHGGEYEAPRKFSRFFGGSTTKKRQRLVMVTSSGRIIMAASGGDEKKAKLELSLLTPGTSYRTSTDSKGFSCWVVDTRDKHFVFEDPKPSSSNVGATAISAQEWLDSLDRAREMALSQQGNGSYSDDAFRDLSSGLSSHANTLDRSSEIQNESAPAGRATLVKHQNTDTESVKGKKRFSRRHSKNGLAAVF 841
<210>2
<211>458
<212> PRT
<213>Aspergillus niger
<400>2
MGNNPSKPPAGDAQSPSAPSAAAGDKKVARRSSIHTPSGTTKASAADPSATRETATGHPTSQAQPSVQQRLQSRNVTDLPTRNLDRPDRQVPKKPDTRSKDIPAPDPSNPVQVPGSRAAAKRDPVAPSGPPPHAYYSASVHLQRPPRMPLPIGDATATPGSPIIGPEDSYMGSVAPDHLLDEHHQSRQSAVSGATVDDDEALDELQPYTPSGVGRAVPTLIEWTAPGDKVYVTGTFVNWEKKFRLHRSENNPGVLSTRLNLRPGTHHLKFIVDGEMRASDNLPTAVDFTNHLVNYIEISADDVNRSRRESDKVPDGVRPPQVIPGPVGNDQVGSTVEEQSDREEPEEIPLGDFRGVIPQFLLDLDREEETPEYQQAVNIVGDAPTPPSLPLFLGKSILNGTTPMKDDSSVLNYPNHTVLNHLATSSIKNGVLATSVTTRYKRKYVTTILYKPTGDITD 458
<210>3
<211>537
<212> PRT
<213>Aspergillus niger
<400>3
MADTTQAPINGGYPAQHAYPDSFTHAPANVNSAASFQPAPSSTPSNAPANDQKNGISKDEVGWYFVEQYYTNMSRSPEKLHLFYSRRSQLVFGTEAETVQVAVGQKAINDKIKQLDFQDCKVRVLNVDSQASFDNILISVIGEISNRSEPSRKFVQTFVLAEQPNGYYVLNDIFRYLVDEEEEIEQEEAAPAAAPAAPAAPVEEPAAEEPAQPEAETVPEPEKAQVDSEPAAAQVDEKLEEAEQTAEAKPAKEDAPQTNGTAAQETPVEAAPEAAAPVETEAPKAEKPATPEPTPVPEQKEAPAPVKESAPARAVPKTWATIASKSGASAPVVPAVPVAPVKPAPAASSAQPTAPAPAPAAAPAPAAAAAPEAASSQPSSTDGSGWQTAGHDHKKTQSRAGEENVLAYIKNVTEKVDASLLKQTLSRFGKLKHFDVSRAKNCAFVEFGDAAGYAAAVAANPHQIGTEQIYVEERRPRTNAFGNGSYGAGRGGAGRGRGDRAGSQGRGGFQREGRGGFAPRGRGGNVNAKGRNQAQTA 537
<210>4
<211>1063
<212> PRT
<213>Aspergillus niger
<400>4
MVATFSPHRDAGGTLHLPSHTGIHHMDANSAIRQLRRSLSRSPSKSSNFSLLASRGHSPSKTAPYISSPLSPSRRSTQSNFVLFPSSSHQSPFAVPYHPSGKITRPTMRRVRTSPRSPVKRALNVSTDQGNAKPAPSVPTTPGVENTPSTPGLVQPDNAARDIFPSDTPACAESTLGPRPALSRIEKRRSGTFGSYATVSPLKRSDGIMNLDRVSRGSPSAKRRSVQAASLSGEFSIFDNEVTPNNAEEPEVEAFPESTTPSFPPPITPFSPFATIPKRSSSLRRSTLQQRQSDRSLFARAKAMDDSPDALDNGTPLSVRPRMSLDQNLFQPNRDSPFLSRPSPGTPLFASTGNNAEQPRPSAHPLSRTITQSSSSSSLGDDSPTHEPVHKGDRPRGIINFSKSLPAGTARPAPLRHLNREDSTSSVDSFATPENYKLVKPLPAAFMSTGLISKKNRNADDPQNTLGFSKNMPDTPCKRPINLFPTGGRIQPERPLEMSGLVRQSDTIPPSPFNPSSTRPKSGPFARGMGIFGSSFNRPEVSRRGSFASIDGDDLLPSQSPCGRNSQPLSENDFPPTPTKQSFFPSRTYPPPVSQIASLERLAEAKGTNSSPLHDRFLRGSPRTPQDHLFPDPSGLSISNEQQSGQPDFNSSNLPATPTGPRDSFQSGKRPSLPLAGYHAPDVDPSLTSRFERVELVGTGEFSQVYRVSEPHDTSISTYPSEMFPPKVLPEQVWAVKKSKQPYSGLKDRERRIREVDILKSLTNADHIISFMNSWEDSGHLYIQTEFCEEGSLDVFLAQVGLKARLDDFRIWKIMLELSMGLKHIHDMGFIHLDLKPANILITFEGVLKIADFGMAARWPAEDGIEGEGDREYIGPEILMGRYDKPADIFSLGLIMFEIAGNVELPDNGLSWQKLRNGDMSDIPSLTWSFETSVFRDASGNPISEEPSFEELCTSDFGEDDYGTDSFLGGRTSKRDMTSTARIGELVDPPSFMVDAGHEQALDKIVRWMISPEPLDRPTADQVLETYGVQFVARRRRAGATVYEGNWGPADEVLAEDAEMIDV 1063
<210>5
<211>767
<212> PRT
<213>Aspergillus niger
<400>5
MMLTEPSFSFSFSYPNGEPQTPTRTPPTTTIFGDSAFQTPKLESSFFDPRVTWDTSDPYASSPEFLRTPQKFGLSTPSINPLRLPDTAPDRPTDTEDNSRNGKAAEQDTDTAKRRRPSRPHGHVGDDGPRTVDSAKSAATIQTPPPSSASRKKVTGLDEATGTGRRPSASSMVGGHLETPSRLLGASPRLFGDLQSSPDPFQLGAIDSAASTFFPQQRLFWDHDFNQHESNMGLSASNNLDLFDLHANDSFHVNHTTAPDSHIPQLPIIEGNTDLPDFNSSTYNLSSGVTTTDAALFPAPFSTSPRRPITKAEDPALFLSSPARRFGGLQPTPEKRLFSRPTRQPYHHQTEESKREELRRARSVNHHIPVYEDDDDDDYTPRQMRPALTRSLTHSAIAGSASRSASGCMMASNGIRKSPSKGRSSPIKPIRHQLSRANSVAASLPRRSQSVVLKIGKDGRAKAEMQPVPEASTGLTDPLTGMDLDGSTTESEYDSVDYCEYPLVPSRNPSFAFSDASGATIARSDCGSRPHSKGSYTSTAASSSGRASPWADAGRGPSRRPQYKPTLDDWKRTPKKQLTTLHSDLSYLSAGSLGEPFADPEDDSGDAQHALRKVLQERGRIPRPHTVSYGSRISRSARSLAHLRSSPPRFGAELDLSSRTTNTSPTTMTDPDIATPVTDRFSNPSNGTRCVCNSMDNGGHLMIQCESCSHWLHTKCVGLERANLPSVYVCIFCAQTPTRKNHRVRVPVGAPGHAPTSPLAHKSYRFR 767
<210>6
<211>524
<212> PRT
<213>Aspergillus niger
<400>6
MSSTTSSSRSDLEKVPVPQVIPRDSDSDKGSLSPEPSTLEAQSSEKPPHHIFTRSRKLQMVCIVSLAAIFSPLSSNIYFPALDDVSKSLNISMSLATLTITVYMIVQGLAPSFWGSMSDATGRRPVFIGTFIVYLVANIALAESKNYGELMAFRALQAAGSAATISIGAGVIGDITNSEERGSLVGIFGGVRMLGQGIGPVFGGIFTQYLGYRSIFWFLTIAGGVSLLSILVLLPETLRPIAGNGTVKLNGIHKPFIYTITGQTGVVEGAQPEAKKTKTSWKSVFAPLTFLVEKDVFITLFFGSIVYTVWSMVTSSTTDLFSEVYGLSSLDIGLTFLGNGFGCMSGSYLVGYLMDYNHRLTEREYCEKHGYPAGTRVNLKSHPDFPIEVARMRNTWWVIAIFIVTVALYGVSLRTHLAVPIILQYFIAFCSTGLFTINSALVIDLYPGASASATAVNNLMRCLLGAGGVAIVQPILDALKPDYTFLLLAGITLVMTPLLYVEDRWGPGWRHARERRLKAKANGN 524
<210>7
<211>24
<212>DNA
<213> artificial sequence
<400>7
caccatctctacctccatcatgga 24
<210>8
<211>24
<212>DNA
<213> artificial sequence
<400>8
aaactccatgatggaggtagagat 24
<210>9
<211>24
<212>DNA
<213> artificial sequence
<400>9
caccgttctggtgcttaaccagtg 24
<210>10
<211>24
<212>DNA
<213> artificial sequence
<400>10
aaaccactggttaagcaccagaac 24
<210>11
<211>24
<212>DNA
<213> artificial sequence
<400>11
caccatcctacaagcgccttccac 24
<210>12
<211>24
<212>DNA
<213> artificial sequence
<400>12
aaacgtggaaggcgcttgtaggat 24
<210>13
<211>24
<212>DNA
<213> artificial sequence
<400>13
cacctctgtgagtccgtgacaaag 24
<210>14
<211>24
<212>DNA
<213> artificial sequence
<400>14
aaacctttgtcacggactcacaga 24
<210>15
<211>24
<212>DNA
<213> artificial sequence
<400>15
caccatacgaggctaggcttgatg 24
<210>16
<211>24
<212>DNA
<213> artificial sequence
<400>16
aaaccatcaagcctagcctcgtat 24
<210>17
<211>24
<212>DNA
<213> artificial sequence
<400>17
cacccgtaccaatgccttcggtaa 24
<210>18
<211>24
<212>DNA
<213> artificial sequence
<400>18
aaacttaccgaaggcattggtacg 24
<210>19
<211>24
<212>DNA
<213> artificial sequence
<400>19
cacccggtctcatcttaccagatt 24
<210>20
<211>24
<212>DNA
<213> artificial sequence
<400>20
aaacaatctggtaagatgagaccg 24
<210>21
<211>24
<212>DNA
<213> artificial sequence
<400>21
cacctgtcggtctagccagtgaca 24
<210>22
<211>24
<212>DNA
<213> artificial sequence
<400>22
aaactgtcactggctagaccgaca 24
<210>23
<211>24
<212>DNA
<213> artificial sequence
<400>23
caccttcctgctcactcctgttga 24
<210>24
<211>24
<212>DNA
<213> artificial sequence
<400>24
aaactcaacaggagtgagcaggaa 24
<210>25
<211>24
<212>DNA
<213> artificial sequence
<400>25
cacctgttgcacactagctatcgc 24
<210>26
<211>24
<212>DNA
<213> artificial sequence
<400>26
aaacgcgatagctagtgtgcaaca 24
<210>27
<211>20
<212>DNA
<213> artificial sequence
<400>27
ggttggagattccagactca 20
<210>28
<211>24
<212>DNA
<213> artificial sequence
<400>28
aaaaaagcaccgactcggtgccac 24
<210>29
<211>57
<212>DNA
<213> artificial sequence
<400>29
cccctccccccccaaaaaggtttggtgtatcaccaaaccccaggaaacagctatgac 57
<210>30
<211>58
<212>DNA
<213> artificial sequence
<400>30
gactgaatcgcttcttgcctttgacggactccgtgtctgttgtaaaacgacggccagt 58
<210>31
<211>57
<212>DNA
<213> artificial sequence
<400>31
ttaatacggcattggacccgcctgactcagttccctttcccaggaaacagctatgac 57
<210>32
<211>58
<212>DNA
<213> artificial sequence
<400>32
gtttgtacaatatcgttgtgacgtactacataccattagttgtaaaacgacggccagt 58
<210>33
<211>57
<212>DNA
<213> artificial sequence
<400>33
tcggggaatatttcttactagatttttttcccttccctcgcaggaaacagctatgac 57
<210>34
<211>58
<212>DNA
<213> artificial sequence
<400>34
cacgaccacgaccggcaccaccgcggcccgcaccgtagcttgtaaaacgacggccagt 58
<210>35
<211>57
<212>DNA
<213> artificial sequence
<400>35
ttttcctagcattccaccgcggtcaacaacaacttccgaccaggaaacagctatgac 57
<210>36
<211>58
<212>DNA
<213> artificial sequence
<400>36
tgccacccgcatcacggtgcggcgaaaatgtcgcgaccattgtaaaacgacggccagt 58
<210>37
<211>57
<212>DNA
<213> artificial sequence
<400>37
tggtctccttttttcactttttcctgctcactcctgttgacaggaaacagctatgac 57
<210>38
<211>58
<212>DNA
<213> artificial sequence
<400>38
agctgaagctgaacgagaaagacggctctgtcagcatcattgtaaaacgacggccagt 58
<210>39
<211>21
<212>DNA
<213> artificial sequence
<400>39
ctccttttccttcccagcttc 21
<210>40
<211>23
<212>DNA
<213> artificial sequence
<400>40
ggaaactctcagggatatcaagc 23
<210>41
<211>21
<212>DNA
<213> artificial sequence
<400>41
cccatcgcattctttctcttc 21
<210>42
<211>20
<212>DNA
<213> artificial sequence
<400>42
ggtctcttatcctccagctc 20
<210>43
<211>21
<212>DNA
<213> artificial sequence
<400>43
ccacctttctatctttcattg 21
<210>44
<211>23
<212>DNA
<213> artificial sequence
<400>44
ggaagggctaggaatcatataag 23
<210>45
<211>20
<212>DNA
<213> artificial sequence
<400>45
gccctcatccacacactctt 20
<210>46
<211>20
<212>DNA
<213> artificial sequence
<400>46
ggcgtgtcacttggaaagat 20
<210>47
<211>23
<212>DNA
<213> artificial sequence
<400>47
tttggagcagcctcatttgtcac 23
<210>48
<211>23
<212>DNA
<213> artificial sequence
<400>48
gaattgtcctcagtgtctgtcgg 23
Claims (9)
1. An engineered bacterium that produces citric acid, wherein An endogenous active polypeptide is inactivated, wherein the endogenous active polypeptide is An01g02600, an01g10200, an02g01210, an02g05870, an02g08630, an02g14400, an05g00280, an07g04000, an08g03270, an08g05190, an09g06580, an13g 00140, or An15g00910, or a homologous gene thereof, corresponding to the aspergillus niger CBS513.88 genome;
preferably, the endogenous active polypeptide is any one of (a) - (b):
(a) Comprising SEQ ID NO:1 to SEQ ID NO:5, or a polypeptide having an amino acid sequence as set forth in any one of claims;
(b) And SEQ ID NO:1 to SEQ ID NO:5 above 98% and derived from an endogenous active polypeptide of aspergillus niger;
more preferably, inactivation of the endogenous polypeptide refers to a decrease or disappearance of the activity of the polypeptide, or a decrease or disappearance of the expression level of the gene encoding the polypeptide;
still further, inactivation of the endogenous polypeptide may be accomplished by one or a combination of the following methods: partial or complete knockout of the gene encoding the polypeptide; mutation of the coding gene; altering the promoter, translational regulatory region or coding region codon of the coding gene to attenuate transcription or translation; altering the coding gene sequence to make its mRNA stability weakened or make the structure of coded protein unstable; or any other gene that is inactivated by modification of the coding region of the gene and adjacent upstream and downstream regions thereof;
further preferably, a reduced activity of an endogenous active polypeptide in said strain relative to an unmodified endogenous active polypeptide means that transcription, expression of a gene encoding said endogenous active polypeptide is reduced by at least 30%, preferably by at least 40%, more preferably by at least 50%, such as by at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or is completely absent; or the activity of the endogenous active polypeptide is reduced by at least 30%, preferably by at least 40%, more preferably by at least 50%, e.g. by at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or is completely absent.
2. The engineered bacterium for producing citric acid of claim 1, wherein SEQ ID NO:1 to SEQ ID NO:5, inactivating a polypeptide having an amino acid sequence set forth in any one of claims; preferably, the citrate production by the citrate producing strain is increased by at least 10%, preferably by at least 20%, more preferably by at least 30% as compared to a wild type strain comprising the endogenous polypeptide.
3. The engineered citric acid producing strain of claim 1 or 2, wherein the activity of a citrate transporter in the production strain is enhanced; preferably, the citrate transporter is a CexA protein with an amino acid sequence shown as SEQ ID NO. 6.
4. An engineered strain for the production of citric acid as claimed in any one of claims 1 to 3, wherein the strain includes but is not limited to aspergillus niger @Aspergilus niger) Aspergillus nidulansAspergillus nidulans) Aspergillus oryzaeAspergillus oryzae) Penicillium chrysogenum (L.) kuntzePenicillium chrysogenum) Trichoderma reesei (Trichoderma reesei)Trichoderma reesei)Semen Maydis black powder fungusUstilago maydis) Myceliophthora thermophila @Myceliophthora thermophila) Any of Aspergillus niger, aspergillus nidulans, aspergillus oryzae, trichoderma reesei are preferred, and Aspergillus niger is most preferred.
5. A method of constructing an engineered bacterium that produces citric acid, the method comprising modifying a wild-type strain comprising an endogenous polypeptide to inactivate the endogenous polypeptide of the wild-type strain, wherein the endogenous active polypeptide comprises any one of (a) - (b):
(a) Comprising SEQ ID NO:1 to SEQ ID NO:5, or a polypeptide having an amino acid sequence as set forth in any one of claims;
(b) And SEQ ID NO:1 to SEQ ID NO:5 above 98% and derived from an endogenous active polypeptide of aspergillus niger;
preferably, inactivation of the endogenous polypeptide refers to a decrease or disappearance of the activity of the polypeptide, or a decrease or disappearance of the expression level of the gene encoding the polypeptide;
still further, inactivation of the endogenous polypeptide may be accomplished by one or a combination of the following methods: partial or complete knockout of the gene encoding the polypeptide; mutation of the coding gene; altering the promoter, translational regulatory region or coding region codon of the coding gene to attenuate transcription or translation; altering the coding gene sequence to make its mRNA stability weakened or make the structure of coded protein unstable; or any other means of inactivating the coding region of the gene by modifying it in its immediate upstream and downstream regions;
further preferably, a reduced activity of an endogenous active polypeptide in said strain relative to an unmodified endogenous active polypeptide means that transcription, expression of a gene encoding said endogenous active polypeptide is reduced by at least 30%, preferably by at least 40%, more preferably by at least 50%, such as by at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or is completely absent; or the activity of the endogenous active polypeptide is reduced by at least 30%, preferably by at least 40%, more preferably by at least 50%, e.g. by at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or is completely absent.
6. The method according to claim 5, wherein the method further comprises enhancing the activity of a citrate transporter in the strain; preferably, the citrate transporter is a CexA protein with an amino acid sequence shown as SEQ ID NO. 6.
7. The method for constructing engineering bacteria for producing citric acid according to claim 5 or 6, wherein the citric acid producing strain comprises but is not limited to Aspergillus nigerAspergilus niger) Aspergillus nidulansAspergillus nidulans) Aspergillus oryzaeAspergillus oryzae) Penicillium chrysogenum (L.) kuntzePenicillium chrysogenum) Trichoderma reesei (Trichoderma reesei)Trichoderma reesei) Semen Maydis black powder fungusUstilago maydis) Myceliophthora thermophila @Myceliophthora thermophila) Any of the strains, etc., is preferably Aspergillus niger, aspergillus nidulans, aspergillus oryzae, trichoderma reesei, and most preferably Aspergillus niger.
8. A method of producing citric acid comprising the steps of:
(1) Culturing the engineering bacteria for producing citric acid according to any one of claims 1 to 4 or the engineering bacteria for producing citric acid constructed by the method according to claims 5 to 7 to produce citric acid; optionally, further comprising:
(2) Separating the citric acid from step (1).
9. Use of the engineering bacteria for producing citric acid constructed by the method of any one of claims 1 to 4 or the engineering bacteria for producing citric acid constructed by the method of any one of claims 5 to 7 in producing citric acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111407487.1A CN116162555A (en) | 2021-11-24 | 2021-11-24 | Engineering bacterium for producing citric acid and construction method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111407487.1A CN116162555A (en) | 2021-11-24 | 2021-11-24 | Engineering bacterium for producing citric acid and construction method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116162555A true CN116162555A (en) | 2023-05-26 |
Family
ID=86411880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111407487.1A Pending CN116162555A (en) | 2021-11-24 | 2021-11-24 | Engineering bacterium for producing citric acid and construction method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116162555A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160060641A1 (en) * | 2013-04-03 | 2016-03-03 | Novozymes A/S | Modified fungal host cells and method of using same |
US20180195052A1 (en) * | 2017-01-12 | 2018-07-12 | Jiangnan University | Method for increasing citric acid production by Aspergillus niger fermentation |
CN110904018A (en) * | 2018-09-14 | 2020-03-24 | 中国科学院天津工业生物技术研究所 | 5-aminolevulinic acid production strain and construction method and application thereof |
CN111088173A (en) * | 2019-12-26 | 2020-05-01 | 南京高新工大生物技术研究院有限公司 | Aspergillus niger genetically engineered bacterium and construction method and application thereof |
CN112250740A (en) * | 2020-10-21 | 2021-01-22 | 中国科学院天津工业生物技术研究所 | Glucose transport protein and application thereof in improving production of organic acid |
CN113265417A (en) * | 2020-02-14 | 2021-08-17 | 中国科学院天津工业生物技术研究所 | Bacterial strain with improved organic acid yield and construction method and application thereof |
-
2021
- 2021-11-24 CN CN202111407487.1A patent/CN116162555A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160060641A1 (en) * | 2013-04-03 | 2016-03-03 | Novozymes A/S | Modified fungal host cells and method of using same |
US20180195052A1 (en) * | 2017-01-12 | 2018-07-12 | Jiangnan University | Method for increasing citric acid production by Aspergillus niger fermentation |
CN110904018A (en) * | 2018-09-14 | 2020-03-24 | 中国科学院天津工业生物技术研究所 | 5-aminolevulinic acid production strain and construction method and application thereof |
CN111088173A (en) * | 2019-12-26 | 2020-05-01 | 南京高新工大生物技术研究院有限公司 | Aspergillus niger genetically engineered bacterium and construction method and application thereof |
CN113265417A (en) * | 2020-02-14 | 2021-08-17 | 中国科学院天津工业生物技术研究所 | Bacterial strain with improved organic acid yield and construction method and application thereof |
CN112250740A (en) * | 2020-10-21 | 2021-01-22 | 中国科学院天津工业生物技术研究所 | Glucose transport protein and application thereof in improving production of organic acid |
Non-Patent Citations (3)
Title |
---|
TIMOTHY C. CAIRNS等: "A quantitative image analysis pipeline for the characterization of filamentous fungal morphologies as a tool to uncover targets for morphology engineering: a case study using aplD in Aspergillus niger", METHODOLOGY, vol. 12, 15 June 2019 (2019-06-15), pages 4 * |
张晓立等: "黑曲霉柠檬酸工业菌株原生质体制备与转化", 生物技术通报, vol. 31, no. 3, 26 March 2015 (2015-03-26), pages 171 - 177 * |
秦郦等: "黑曲霉菌株柠檬酸合成酶基因的敲除及功能分析", 微生物学通报, vol. 47, no. 6, 6 January 2020 (2020-01-06), pages 1740 - 1752 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5052899B2 (en) | Gene expression method | |
DK2875119T3 (en) | AGSE-DEFICIENT TRIALS | |
EP2565262A1 (en) | Protein expression | |
GB2582100A (en) | CAS12C Compositions and methods of use | |
CN103003438B (en) | Reduce Method and Process and the protein thereof of Protein Glycosylation Overview | |
EP3374377A1 (en) | Wap genes and proteins that improve bacillus competitiveness | |
EP2665812B1 (en) | Expression of plant peroxidases in filamentous fungi | |
JP6864308B2 (en) | Isoamyl Acetate High Productivity, Acetic Acid Productivity Low Productivity and Isoamyl Alcohol High Productivity Method for Producing Brewed Yeast | |
JP6599583B1 (en) | Multigene disrupted Aspergillus microorganism and method for producing the same | |
CN116162555A (en) | Engineering bacterium for producing citric acid and construction method and application thereof | |
CN110592084A (en) | Recombinant strain modified by rhtA gene promoter and construction method and application thereof | |
CN115725489A (en) | Oxidized endotoxin-free escherichia coli genetic engineering strain and construction and application thereof | |
EP4359423A1 (en) | Bacillus licheniformis host cell for production of a compound of interest with increased purity | |
CN110628802B (en) | Sorangium cellulosum for high-yield epothilone D and construction method and application thereof | |
US20080299616A1 (en) | Malate Synthase Regulatory Sequences for Heterologous Gene Expression in Pichia | |
JP6474477B2 (en) | Marker gene | |
CN109715809B (en) | Method for selective carbon source independent expression of protein coding sequences in filamentous fungal cells | |
US20060121564A1 (en) | Novel expression vector suitable for expression of recombinant protein at low temperature | |
CN112105740A (en) | Long-chain non-coding RNA expression in fungal hosts | |
KR20140018850A (en) | Compositions and methods of producing enterokinase in yeast | |
WO2017163946A1 (en) | Induction-type promoter | |
Yamada et al. | Cloning and heterologous expression of the antibiotic peptide (ABP) genes from Rhizopus oligosporus NBRC 8631 | |
JP4413557B2 (en) | Efficient production of proteins using filamentous fungi | |
JP6274502B2 (en) | Method for obtaining a uracil-requiring strain of Cryptococcus having an increased frequency of homologous recombination | |
KR102551064B1 (en) | Novel U6 promoter separated form grapevine and use of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |